tirzepatide 50mg Compounded GLP-1 - Semaglutide &

In individuals with elevated baseline AST/ALT (non-alcoholic fatty liver, alcohol use, medication-related elevation), clinical studies have documented measurable enzyme normalization in the 4-8 week window

These are astounding results given both the magnitude of the weight loss and the time frame in which it occurred (gradual weight loss over 1.3 years) as rapid weight loss is known to be unhealthy and subject to the yo-yo effect

This medication is FDA-approved for promoting weight loss in obese and overweight patients when combined with exercise and a low-calorie diet

Clinical studies demonstrate that GLP-1 medicines can reduce visceral adipose tissue as part of overall weight loss, offering potential benefits for cardiovascular and metabolic health